Continuous Glucose Monitoring and Clinical Outcomes in Diabetes on Peritoneal Dialysis (GLANCE-PD)

Inclusion criteria:

1. Stage 5 CKD patients

   1. who have received PD for at least 3 months, OR
   2. who are planned for PD within the next 3 months.
2. Age 18-80 years old
3. Known history of type 1 or type 2 diabetes for at least 3 months
4. Women who are not pregnant, lactating or planning a pregnancy during their participation in the clinical study.
5. Willingness, ability and commitment to comply with the testing, procedure and follow-up outlined in this protocol including (but not limited to) frequency of clinic visits and use of pre-specified glucose monitoring devices.
6. Willingness to abstain from swimming during their participation in the measurement phase.
7. In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a good study candidate.
8. Written informed consent to participate in the study provided by the patient.

Exclusion criteria:

1. Patients who are planning to switch to hemodialysis or renal transplant in the coming 3 months
2. Life expectancy <6 months
3. Extensive skin changes/diseases that preclude wearing the required number of devices on normal skin at the proposed application sites
4. HbA1c > 11% at enrolment
5. Currently pregnant, as demonstrated by a positive pregnancy test at screening for women of reproductive potential.
6. Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study.
7. Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff.
8. Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device.
9. Have a known allergy to medical-grade adhesives or known hypersensitivity to any of the products used in the study.
10. Have MRI scan, CT scan, or diathermy scheduled during the proposed period of sensor wearing during the study